BALFAXAR
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 29 Jul 2024)
What this means for you
Registered since 30 Oct 2018. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 30 Oct 2028: the §8 & §9 renewal).
Record
- Serial number
- 87648328
- Registration number
- 5593557
- Mark type
- Word mark
- Filed
- 17 Oct 2017
- Published for opposition
- 14 Aug 2018
- Registered
- 30 Oct 2018
- Next maintenance filing
- §8 & §9 renewal, due by 30 Oct 2028 (grace period to 30 Apr 2029)
- Attorney of record
- Rebecca Liebowitz
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products, namely, blood plasma derived products, especially prothrombin for the treatment or prevention of blood or bleeding disorders
Owner
- Octapharma AG, Lachen, CH
- Octapharma AG, Lachen, CH
- Octapharma AG, Lachen, CH
Prosecution history
- 29 Jul 2024 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 29 Jul 2024 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 29 Jul 2024 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 12 Jan 2024 — TEAS SECTION 8 & 15 RECEIVED
- 30 Oct 2023 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 30 Oct 2018 — REGISTERED-PRINCIPAL REGISTER
- 14 Aug 2018 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 14 Aug 2018 — PUBLISHED FOR OPPOSITION
- 25 Jul 2018 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 11 Jul 2018 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 10 Jul 2018 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 10 Jul 2018 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 06 Jul 2018 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 31 Jan 2018 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 31 Jan 2018 — NON-FINAL ACTION E-MAILED